Bocom International has issued a research report maintaining its investment rating and price target for GENFLEET-B (ASX: 02595) at 'Buy' and HK$51, respectively.

The bank noted that the overseas clinical development and partnership progress for the KRAS G12D inhibitor are progressing favorably.

Bocom International believes that the strong preliminary overseas data provides further evidence supporting the best-in-class potential of VS7375.

In the second half of 2026, Verastem is expected to disclose additional efficacy data from the TARGET-D 101 study, which warrants close attention.

Other key overseas catalysts include: 1) completing patient enrolment for the TARGET-D 101 pancreatic cancer and NSCLC monotherapy cohorts and the CRC combination cohort by the end of June; 2) discussing the design of a first-line Phase III study with the FDA by the end of 2026 and initiating patient enrolment in the first half of 2027.